Page 18 - Klaus Sindahl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company s antibody-cleaving enzyme technology platform

Proceeds will be mainly utilized to: - Further strengthen the Company s position in kidney transplantation through the continued support of ongoing European.

Hansa biopharmaPhilip nunesPrnewswire hansa biopharmaKlaus sindahlBrett fleshmanDonato spotaKatja margellDrug administrationBackbay communicationsHead of corporate communicationsBiologics license applicationNasdaq stockholmNovaquest capital managementChief financial officerManaging directorProduct finance

Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, announces today that the.

Comunidad autonoma de catalunaHansa biopharmaVincenza nigroKlaus sindahlOriol bestardKatja margellChristian kjellmanEuropean unionHebron university hospitalEuropean medicines agencyEuropean medicines agency ema priorityHead of corporate communicationsNasdaq stockholmKidney transplantationChief scientific officerKidney transplant franchise lead

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, has today on June 30,.

United statesHansa biopharmaAndreas eggertKlaus sindahlEva nilsagAnders gersel pedersenHilary malonePrnewswire hansa biopharmaPeter nicklinKatja margellShare rights programAudit committeeRemuneration committeeHansa biopharma option programNomination committeeExchange commission

NICE recommends use of Hansa Biopharma s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

NICE recommends use of Hansa Biopharma s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomNorthern irelandAdnan sharifHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlKatja margellNational institute for healthEuropean unionEuropean commissionEuropean medicines agencyEuropean medicines agency ema priorityKidney research united kingdomRegulatory agencyNasdaq stockholmNational institute

Hansa Biopharma: Notice to Annual General Meeting

Hansa Biopharma: Notice to Annual General Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAndreas eggertHansa biopharmaStefan lundbergJannis kitsakisHansa biopharmahansa biopharmaPrnewswire hansa biopharmaPeter nicklinAdvokatfirman vingeNovartis pharmaRelationshansa biopharmaHamann girrbachKlaus sindahlEva nilsagLaura feinleib